TY - JOUR
T1 - Latanoprost therapy reduces the levels of TGF beta 1 and gelatinases in the aqueous humour of patients with exfoliative glaucoma
AU - Konstas, Anastasios G.P.
AU - Koliakos, George G.
AU - Karabatsas, Costas H.
AU - Liakos, Panayiotis
AU - Schlötzer-Schrehardt, Ursula
AU - Georgiadis, Nikolaos
AU - Ritch, Robert
N1 - Funding Information:
This research was supported by ENTER and PENED grants (Greek Ministry of Development and E.U.) and grant 912-OPT-0091-149 from Pfizer Ophthalmics (New York, USA) to Dr AGP Konstas. The authors acknowledge the excellent technical assistance of Ms Melpomeni Christophoridou and the help of Dr Ioannis Tersis and Ms Maria Economopoulou with the aqueous samples.
PY - 2006/2
Y1 - 2006/2
N2 - The aim of the present study was to evaluate the effect of latanoprost monotherapy on the aqueous humour concentrations of TGF-β1, MMP-2, TIMP-2, MMP-9 and gelatinolytic activity in patients treated for exfoliative glaucoma (XFG). Aqueous samples from 50 XFG patients treated with latanoprost and 50 age-matched XFG patients treated with timolol were collected during phacoemulsification cataract surgery. The concentrations of TGF-β1, MMP-2, TIMP-2, MMP-9 and gelatinase activity were determined by commercial immunoassays. The mean active TGF-β1 concentration in the aqueous was significantly lower in XFG patients treated with latanoprost compared with those treated with timolol (3.1±0.65 vs 13.4±1.5 pg ml-1); (P=0.0014). The mean total MMP-2 concentration was lower in latanoprost treated patients (31.75±3.8 vs 81.5±7.2 ng ml-1); (P<0.0001). The TIMP-2 concentration was also lower in XFG-latanoprost treated patients (73.8±6.81 vs 101.28±7.29 ng ml-1); (P=0.0096). Latanoprost monotherapy has a marked effect on the aqueous concentration of TGF-β1, MMP-2 and TIMP-2 in XFG patients. A better understanding of its effect on the pathobiology of the disease may lead to its earlier use in the disease process to prevent progression from XFS to XFG.
AB - The aim of the present study was to evaluate the effect of latanoprost monotherapy on the aqueous humour concentrations of TGF-β1, MMP-2, TIMP-2, MMP-9 and gelatinolytic activity in patients treated for exfoliative glaucoma (XFG). Aqueous samples from 50 XFG patients treated with latanoprost and 50 age-matched XFG patients treated with timolol were collected during phacoemulsification cataract surgery. The concentrations of TGF-β1, MMP-2, TIMP-2, MMP-9 and gelatinase activity were determined by commercial immunoassays. The mean active TGF-β1 concentration in the aqueous was significantly lower in XFG patients treated with latanoprost compared with those treated with timolol (3.1±0.65 vs 13.4±1.5 pg ml-1); (P=0.0014). The mean total MMP-2 concentration was lower in latanoprost treated patients (31.75±3.8 vs 81.5±7.2 ng ml-1); (P<0.0001). The TIMP-2 concentration was also lower in XFG-latanoprost treated patients (73.8±6.81 vs 101.28±7.29 ng ml-1); (P=0.0096). Latanoprost monotherapy has a marked effect on the aqueous concentration of TGF-β1, MMP-2 and TIMP-2 in XFG patients. A better understanding of its effect on the pathobiology of the disease may lead to its earlier use in the disease process to prevent progression from XFS to XFG.
KW - Aqueous humour
KW - Exfoliative glaucoma
KW - Latanoprost
KW - TGF beta
KW - Timolol
UR - https://www.scopus.com/pages/publications/31044456432
U2 - 10.1016/j.exer.2005.07.004
DO - 10.1016/j.exer.2005.07.004
M3 - Article
C2 - 16115621
AN - SCOPUS:31044456432
SN - 0014-4835
VL - 82
SP - 319
EP - 322
JO - Experimental Eye Research
JF - Experimental Eye Research
IS - 2
ER -